Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : EU regulator to decide on Pfizer booster at the start of October - source

09/23/2021 | 05:51am EDT

BRUSSELS, Sept 23 (Reuters) - The European Medicines Agency (EMA) expects to decide in early October on the possible use of a booster dose of the Pfizer-BioNTech COVID-19 vaccine, a source with direct knowledge of the matter told Reuters.

It will be the EU drugs regulator's first decision on boosters, the source said, after the U.S. Food and Drug Administration on Wednesday authorized a third dose of Pfizer for those 65 and older, all people at high risk of severe disease, and others who are regularly exposed to the virus.

"EMA's decision on the third dose of Pfizer is expected for the beginning of October," the source said, declining to be named because of the sensitivity of the matter.

Pfizer declined to comment, while BioNTech was not immediately available for comment.

The EU regulator said on Sept. 6 it had begun its evaluation of data submitted by Pfizer and BioNTech for a booster dose to be given six months after the second dose in people 16 years of age and older.

Moderna is also expected to submit data to the EMA this month on its booster dose, an EU document said.

In an opinion issued in early September and republished by the EMA, the European Centre for Disease Prevention and Control (ECDC) said there was no urgent need to administer booster doses to fully vaccinated individuals in the general population.

But it also noted that additional doses should already be considered for people with severely weakened immune systems as part of their primary vaccination.

Many EU states have already decided to administer a booster dose despite facing higher legal risks without a formal decision to do so by the EMA.

The EU has signed three deals with Pfizer and BioNTech for a total of 2.4 billion doses.

The latest contract covers the supply of at least 900 million shots, a large part of which is likely to be needed only if boosters are considered necessary, or if new virus variants emerge against which existing vaccination is not effective.

Over 70% of the EU's adult population has already been fully vaccinated, and the bloc has secured an ample supply of vaccines from several manufacturers.

The ECDC has said crucial data on the need and safety of boosters are still missing, in part because it is not yet fully clear how long vaccines protect against the virus. (Reporting by Emilio Parodi and Francesco Guarascio @fraguarascio; Additional reporting by Ludwig Burger; Editing by Josephine Mason and Jan Harvey)


© Reuters 2021
All news about MODERNA, INC.
10/20MODERNA : US FDA OKs Booster Shots for Moderna, Johnson & Johnson's COVID-19 Jabs
MT
10/20EMEA MORNING BRIEFING : Stocks to Struggle as -2-
DJ
10/20MODERNA : Announces FDA Authorization of a Booster Dose of Moderna's COVID-19 Vaccine in t..
BU
10/20FDA Authorizes Booster Shots for Moderna, J&J Vaccines; Greenlights Mixing Brands
MT
10/20U.s. fda clears moderna and j&j boosters, backs 'mix-and-match' strategy
RE
10/20MODERNA : U.S. FDA clears Moderna and J&J boosters, backs 'mix-and-match' strategy
RE
10/20MODERNA : J&J Covid-19 Vaccine Boosters Reportedly Receive FDA Authorization, Bloomberg Sa..
MT
10/20MODERNA : US regulators allow mixing of COVID-19 shots for boosters and clear booster Mode..
AQ
10/20MODERNA : U.S. administers 410.2 mln doses of COVID-19 vaccines - CDC
RE
10/20SANOFI : says its flu vaccine can be co-administered with Moderna's COVID-19 shot
RE
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 20 335 M - -
Net income 2021 12 514 M - -
Net cash 2021 12 947 M - -
P/E ratio 2021 11,2x
Yield 2021 -
Capitalization 134 B 134 B -
EV / Sales 2021 5,97x
EV / Sales 2022 5,24x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Last Close Price 333,01 $
Average target price 299,31 $
Spread / Average Target -10,1%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.218.76%134 418
LONZA GROUP AG27.07%58 240
IQVIA HOLDINGS INC.40.38%47 715
SEAGEN INC.-0.17%31 691
CELLTRION, INC.-39.00%25 332
ALNYLAM PHARMACEUTICALS, INC.56.82%24 553